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Abstract Partial cDNAs of the ryanodine receptor were cloned 
using PCR analysis from reverse transcribed total and mRNA, 
extracted from freshly isolated pregnant, non-pregnant, and cul- 
tured human myometrial smooth muscle. The identity of these 
clones was confirmed by nucleotide sequencing of the fragments 
and indicate the expression of both the skeletal and brain ryan- 
odine receptor isoforms in these preparations. In freshly isolated 
non-pregnant myometrial tissue, membrane fractions displaying 
specific [3H]ryanodine binding activities were isolated using den- 
sity gradient centrifugation. SDS-PAGE of the sucrose gradient 
fractions indicated the specific comigration of a polypeptide with 
a molecular mass of~544 kDa with the ryanodine binding activity. 
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1. Introduction 
The uterus undergoes regular spontaneous activity both in 
vivo and in vitro and this activity may be modulated by agonists 
such as oxytocin and prostaglandins [1]. These substances bind 
to specific cell membrane receptors which initiate a series of 
biochemical and voltage-regulated pathways that lead to the 
production of transient elevations in cytoplasmic free Ca >, 
from non-mitochondrial intracellular stores and influx from the 
extracellular environment [2]. In human myometrium, both 
oxytocin and vasopressin are known to generate the second 
messenger, inositol 1,4,5-trisphosphate (InsP3) [3], which regu- 
lates the release of intracellular Ca 2+ from an InsP3-sensitive 
store. This involves a specific InsP3 receptor, which modulates 
many processes, such as excitation-contraction coupling and 
the influx of extracellular calcium through cell surface calcium 
channels [4]. A second mechanism capable of releasing intracel- 
lular Ca 2+ is known to exist in skeletal, cardiac and smooth 
muscle which is sensitive to ryanodine and Ca 2+ [4,5,6]. 
Ryanodine has been demonstrated to bind specifically and 
at nanomolar concentrations to the skeletal and cardiac ryan- 
odine receptor Ca 2÷ release channels (RyR) on the sarcoplas- 
mic reticulum (SR). At nanomolar concentrations, ryanodine 
locks the channel into a permanently open subconductance 
state, while at concentrations above 10 ¢tM, ryanodine corn- 
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pletely closes the channel [7,6]. Previous work on cultured 
human myometrial cells has demonstrated that a ryanodine- 
sensitive Ca > release mechanism is operational [8] and prelim- 
inary studies indicate the expression and isolation of a ryan- 
odine binding protein in both myometrial cultured cells and 
whole tissue [9]. 
Three structurally distinct forms of the ryanodine-sensitive 
Ca 2+ release channel complex have been identified, RyR1, 
RyR2 and RyR3 [10,6]. The skeletal (RyR1) and cardiac 
(RyR2) channels comprise 30S homotetrameric complexes of 
~ 565 kDa subunits that form a 'four leaf clover-like' structure 
and display a morphology identical to the 'feet' structures that 
span the T tubule/SR junctional gap [11]. RyR1 is found pre- 
dominantly in skeletal muscle and has also been identified in 
oesophagus and regions throughout the brain [12]. In skeletal 
muscle it is probably directly associated with a dihydropyridine 
receptor protein [13] located in the T tubular membrane. The 
entire complex is thought o operate as a voltage sensor where 
depolarisation of the T-tubular membrane l ads to the release 
of Ca 2+ from the SR. The Ca 2+ sensitivity of the RyR1 system 
may enable positive feedback and the regenerative r lease of 
large quantities of Ca 2+ from the SR [6]. The RyR2 channel 
found in cardiac muscle appears to be entirely dependent on 
cytoplasmic Ca 2+ derived as a result of Ca 2+ influx from the 
external environment [141. Positive feedback of Ca 2+ on RyR2 
leads to the rapid release of Ca 2+ from the cardiac SR. Both 
RyR1 and RyR2 demonstrate similar conductance and phar- 
macological properties as well as 66% identical amino acid 
sequence and similar membrane topology [15]. Functionally, 
RyR1 and RyR2 are potentiated by Ca 2+, ATP and inhibited 
by Mg 2÷ and ruthenium red [6,16]. There are also putative 
binding sites for calmodulin on both the skeletal and cardiac 
ryanodine receptors, located in distinct modulator binding re- 
gions within the protein, which may play an important role in 
the regulation of the Ca 2+ release channel [17]. The skeletal and 
cardiac ryanodine systems are also sensitive to activation by 
caffeine with the cardiac ryanodine channel being most sensi- 
tive [181. 
A third isofonn of the ryanodine receptor/channel complex 
(RyR3) has been identified in rabbit brain and also appears to 
be expressed in mink lung epithelial cells after treatment with 
TGF-fl [19,20]. This isoform appears to be expressed in many 
cell types including rabbit vascular smooth muscle cells [12,20]. 
At present he human RyR3 isoform has only been identified 
and partially sequenced in an established cell line [21]. The 
amino acid sequence of the RyR3 isoform, deduced from the 
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nucleotide sequence of the mink lung and rabbit brain cDNA, 
indicates an overall identity of 70% with both RyR1 and RyR2. 
However, there are few reports which describe the biochem- 
ical and molecular characteristics of the RyR3. Ryanodine 
binding proteins have been isolated from canine and porcine 
aortic smooth muscle where the Ca 2÷ release channel was 
shown to have similar properties to the skeletal and cardiac 
ryanodine receptor channel complexes [22]. Similarly, in toad 
visceral smooth muscle, the purified RyR channel migrated 
with a similar mobility to the cardiac ryanodine receptor on 
SDS-PAGE and cross-reacted with a monoclonal antibody to 
the canine cardiac ryanodine receptor [23], It has also been 
reported that the RyR3 system in mink lung is not activated by 
caffeine [19]. 
This paper describes the expression of two isoforms of the 
ryanodine receptor from human myometrium. Recently it has 
been demonstrated that two ryanodine receptor isoforms are 
expressed in each type of porcine striated muscle and all ryan- 
odine receptor isoforms are expressed in a number of regions 
of the nervous system [12]. The possible functional significance 
of two isoforms expressed in human myometrial smooth muscle 
remains to be determined. Parts of this work have been pub- 
lished in abstract form [9,24]. 
2. Materials and methods 
2.1. Tissue preparation and culture techniques 
Myometrial tissue from the lower uterine segment was taken, with 
informed consent, from patients undergoing either hysterectomy 
(women under 40 years of age) or elective caesarean section. Ethical 
approval was obtained from Newcastle Area Health Authority. My- 
ocytes were prepared using a dispase/collagenase digestion [25] and 
maintained in M199 (Gibco Ltd) supplemented with 10% foetal calf 
serum, 1% glutamine and 2% penicillin/streptomycin. Cells were grown 
to confluence in culture flasks before being passaged onto plastic mul- 
tiwells for 45Ca2+ effiux studies. Cells were not used beyond passage 
number 6. Fresh tissue for isolation of total RNA and mRNA was 
quickly taken and transported frozen in liquid nitrogen. Tissue required 
for the purification of the ryanodine receptor was washed and trans- 
ported, on ice, in 0.3 M sucrose containing protease inhibitors before 
being snap-frozen i liquid nitrogen and stored at -90°C, unless proc- 
essed immediately. 
2.2. 4S Ca 2+ efflux jrom saponin-permeabilised cultured cells 
Confluent cells, grown in 12 well multiwells, were washed with a 
balanced salt solution containing (raM): 135 NaC1, 5.9 KCI, 1.5 CaCI2, 
1.2 MgC12, 11.6 HEPES and 11.5 glucose, pH 7.3 to remove the culture 
medium before being fixed to a mechanical shaker. Cells were permea- 
bilised with 15/lg/ml saponin for 15 min in the following skinning 
solution (mM): 120 KC1, 10 HEPES, 2 MgC12, 1 ATP and 1 EGTA, 
pH 7.0. The efficiency of skinning was routinely checked using Trypan 
blue exclusion staining. Traces of saponin were removed by washing the 
cells with a loading buffer containing (mM): 120 KC1, 10 HEPES, 5 
MgC12, 5 ATP, 0.44 EGTA, 5 NaN3 and 0.12 CaCl2, pH 6.89. The 
mitochondrial Ca2+/ATPase inhibitor NaN3 was used to eliminate any 
contribution of Ca 2+ released from mitochondrial pools to the overall 
efflux of Ca 2÷. Non-mitochondrial ntraceUular stores were loaded with 
10/./Ci of 45Ca2+ per well for 10 min in 0.5ml of the loading buffer. 
Loading was terminated by quickly washing three times in ice cold 
loading buffer prior to the start of ettlux. The efflux buffer contained 
(mM): 120 KC1, 10 HEPES, 1 ATP, 3 EGTA and 5 NaN 3. The amount 
of CaC12 and MgCI2 required to give solutions of known free Ca 2. 
concentration was calculated using the program REACT [26] and rest- 
ing Ca 2. was taken to be 100 nM. 45Ca2+ efflux was monitored at 2 min 
time intervals and the remaining 45Ca2÷ in the cells at the end of efltux 
was determined by solubilising the cells with 2% SDS. All experiments 
were carried out at room temperature (25°C) and the efflux of radiola- 
belled Ca 2+ was determined by liquid scintillation counting. The loss of 
45Ca 2+ at each 2 min time point was calculated from the cpm as a 
fraction of the total 4SCa2+ remaining (including the final SDS fraction) 
within the cells at that time point. 
2.3. cDNA synthesis and reverse transcriptase-polymerase chain 
reaction (RT-PCR) 
Total RNA was extracted from both pregnant and non-pregnant 
human myometrial tissue by the guanidine isothiocyanate/lithium chlo- 
ride method [27]. Prior to first strand cDNA synthesis, samples were 
treated with DNase I (FPLC pure, RNase free, Pharmacia) at 37°C for 
30 min in 6 mM MgCI2, 40 mM Tris-HCl, pH 7.5. Poly(A) ÷ mRNA was 
prepared from cultured myometrial cells using a Quickprep mRNA 
purification kit (Pharmacia), following manufacturers instructions. The 
DNase 1 treated RNA (5/tg or 0.5pg of Poly(A) ÷ mRNA) served as the 
template for first strand cDNA synthesis using avian myeloblastosis 
virus reverse transcriptase (Pharmacia) or Superscript RT (Gibco BRL) 
using 200 U per ~tg RNA. Specific 3' oligonucleotides were used as 
primers for first strand cDNA synthesis. A quarter of the reverse tran- 
scriptase reaction product was amplified, using standard PCR methods, 
in a 100/ll reaction volume using Taq polymerase (BRL Gibco). Ampli- 
fication conditions were as follows: denaturing; 94°C for 5 min, primer 
annealing; 50°C for 2 min, extension; 72°C for 3 min, followed by 30 
cycles of denaturing; 94°C for 1 min, primer annealing; 45°C for 2 min, 
extension; 72°C for 3 rain and one final cycle, denaturing; 94°C for 1 
min, primer annealing; 50°C for 2 min and extension; 72°C for 10 min. 
The amplification conditions for cultured cell cDNA primed with ol- 
igonucleotides designed to the RyR3 sequence were identical except 
that the primer annealing was carried out at 55°C. 
2.4. Synthetic oligonucleotides 
Oligonucleotides were designed from the human type-I ryanodine 
receptor cDNA sequence [28] with incorporated restriction endonu- 
clease sites for subsequent cloning of the PCR amplified products. The 
following oligonucleotides were used: RyRI/5', AAGGTGCCCCTG- 
GAATTCTTTGCGGGAG (sense) containing an EcoRI site and 
RyRI/3', GTGTGTTCTGTCGGATCCTTGTTTATCAAA (anti- 
sense) containing a BamHI site to amplify a product of 999 bp. The 
following oligonucleotides were designed from the reported type 3 
human ryanodine receptor cDNA sequence [21]: RyR3/5', TCACCT- 
ATTGGAATTCGCAATGGGCT (sense) containing an EcoRI site 
and RyR3/3', AGTAGTTGGCTAAGCTTTGCTCTTGTAAT (anti- 
sense) containing a HindlII site to amplify a product of 477 bp. All 
oligonucleotides were obtained from the Molecular Biology Service 
Unit, University of Newcastle upon Tyne. 
2.5. Nucleotide sequencing of the PCR derived type-1 and type-3 
ryanodine receptor clones 
The DNA sequences of the PCR derived clones were determined by 
the dideoxy chain termination method [29] after subcloning appropri- 
ately designed fragments into the vectors M 13mp 18 and M 13mpl 9 [30]. 
Clones from different PCR mediated amplifications of the ryanodine 
receptor f agments were sequenced toverify that the amplified products 
were homogeneous and specific. The preparation of oligonucleotides 
and sequencing were performed as previously described [29,30,31]. 
2.6. Isolation of heavy SR vesicles from myometrial smooth muscle 
Heavy SR vesicles were prepared from human myometrium obtained 
at hysterectomy using previously described methods [32]. The tissue was 
minced and homogenised in 7 vols. of ice-cold 0.1 M NaC1, pH 7.5, 
containing 10 mM Tris-HEPES, 0.5 mM EDTA and protease inhibitors 
(0.1 mM aprotinin, 1/IM leupeptin, 1/IM pepstatin, I mM benzamidine 
and 0.2 mM PMSF) at 4°C for 2 x 30 s periods in a Waring blender, 
followed by centrifugation at2600 x g for 25 min at 4°C. The superna- 
tant was then filtered through two layers of cheesecloth and centrifuged 
at 33000 × g for 30 rain at 4°C. The resulting pellets were resuspended 
in extraction buffer (0.6 M KCI/10 mM KPipes, pH 7.0), containing 100 
HM EGTA, 90 ,uM Ca 2÷, 0.2 mM PMSF and 1/,tM leupeptin, and left 
on ice for 60 min. The suspension was centrifuged at 35000 x g for 60 
min at 4°C and the pellets were resuspended in extraction buffer and 
layered on the top of a 20-45% (w/w) linear sucrose gradient. The 
gradients were centrifuged at26000 × g for 16 h at 2°C and the resulting 
gradients fractionated into 2 ml fractions. Membranes sedimenting at
25-35% sucrose were collected, diluted with 2 vols. of 0.4 M KCI, 
centrifuged at 30000 ×g for 60 min at 2°C, resuspended in 0.3 M 
sucrose, 5 mM KPipes, pH 7.0 and stored at -80°C. Protein was 
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determined for each fraction by the method of Lowry et al. [33] using 
BSA as a standard. 
2. 7. FHJRyanodine binding assay 
Heavy SR vesicles containing the RyR were incubated at 12°C for 
approx. 24 h in 100 pl of reaction mixture containing 20 mM KPipes, 
pH 7.4, 0.6 M KCI, 50/IM EGTA, 200 ArM Ca 2+, 6 mM AMR 0.1 mM 
PMSF, 10 mM leupeptin and 12.5 nM [3H]ryanodine. Bound and free 
[3H]ryanodine were separated by a filter assay [34] with several modifi- 
cations. Aliquots of 40/A of the vesicle suspensions were diluted 25-fold 
with ice-cold water, placed on a Whatman GF/B glass fibre filter pre- 
soaked in 1% (w/v) polyethyleneimine, and rinsed three times with 5 ml 
of ice-cold 0.1 M KCI, 1 mM KPipes, pH 7.0. Total radioactivity and 
bound radioactivity as determined after filtration were measured by 
liquid scintillation counting. Non-specific binding, which was assumed 
to be linear with respect o ryanodine concentration, was determined 
in the presence of 1 mM unlabelled ryanodine. 
2.8. SDS-PAGE 
Samples were electrophoresed in 4-15% gradient gels, using the Phar- 
macia Phastsystem with the buffer system of Laemmli [35]. Samples 
were denatured at 90°C for 5 min in 2% SDS, 2.5% fl-mercaptoethanol, 
0.1 M Tris-HC1, pH 6.8 and 10% glycerol, and electrophoresed at 15 ° C. 
Gels were stained with 0.05% Coomassie brilliant blue R250 in 30% 
methanol and 10% acetic acid. 
2.9. Materials 
[45Ca2+]-, [35S]- and [3H]ryanodine were purchased from Amersham 
International, U.K. Medium 199 and other tissue culture materials 
were from Gibco Ltd, UK. Ryanodine and caffeine were obtained from 
Sigma Chemical Co., Poole, Dorset, UK. RNase-free DNase I, reverse 
transcriptase and Klenow fragment were from Pharmacia, Uppsala, 
Sweden and Superscript RT from Gibco BRL. All oligonucleotide 
probes were produced by the University Facility for Molecular Biology, 
University of Newcastle upon Tyne. Taq polymerase was from BCL, 
UK. All other chemicals used were of analytical grade or greater. 
3. Results 
3.1. 45 Ca2+ efflux from permeabilised cultured cells" 
3.1.1. Effects of ryanodine and caffeine. Microspectrofluori- 
metry of intact cultured myometrial cells with Fura-2 suggested 
that a ryanodine-sensitive, caffeine-insensitive Ca 2+ release 
mechanism ay be operational [8]. In order to directly demon- 
strate a caffeine-insensitive, ryanodine-sensitive Ca 2+ release 
activity, the non-mitochondrial stores of permeabilised human 
myometrial cells were loaded with 45Ca 2+. Using this technique, 
the composition of the medium bathing the cells can be con- 
trolled accurately and experimental solutions may be directly 
exposed to the internal membranes. The effects of caffeine and 
ryanodine were examined in permeabilised cultured cells and 
Fig. 1A illustrates the effect of 10 mM caffeine on the basal 
efflux of 45Ca 2+. The results indicate that there is no caffeine- 
induced Ca 2+ release in these cells. Fig. 1B demonstrates a 
typical response obtained from 4SCa2+ loaded cells to a 2 min 
incubation with 1/.tM ryanodine (l).  Ryanodine increased the 
rate of 4SEa2+ loss at 1 ¢tM, confirming the presence of a ryan- 
odine-sensitive Ca 2÷ release process. However, this ryanodine- 
sensitive Ca 2+ release was augmented in the presence of 10 mM 
caffeine (o). 
3.1.2. Isolation of a ryanodine binding protein from whole 
tissue. Experiments were performed to confirm the 
presence of a ryanodine receptor/channel in human myometrial 
cells. Freshly isolated non-pregnant tissue obtained from hys- 
terectomy was used for membrane preparation since the large 
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Fig. 1. Effect of ryanodine and caffeine on 45Ca2+ efflux from permea- 
bilised myometrial smooth muscle cells. (A) 45Ca2+ efflux from saponin- 
permeabilised cells under control conditions (I) and after a 2 min 
application of 10 mM caffeine (e). (B) The effects of 10 mM caffeine 
on the response to 1/~M ryanodine in permeabilised cultured human 
myometrial smooth muscle cells. (I) shows a control response to a 2 
min application of ryanodine (arrow) and (e) shows the augmentation 
of the 1//M ryanodine-induced Ca 2÷ release in the presence of caffeine. 
Caffeine was applied throughout the time course of efflux. Experiments 
were carried out at room temperature. The data presented are typical 
of six paired experiments. 
amount of tissue required could not be obtained easily from the 
culture system. A heavy membrane fraction was isolated and 
specific [3H]ryanodine binding could be detected in the 25 35% 
sucrose region of the sucrose density gradient (Fig. 2A). Fig. 
2B compares pecific [3H]ryanodine binding to the pooled frac- 
tions from the lower third of the gradient and a comparable SR 
membrane fraction isolated from rabbit skeletal muscle. The 
specific [3H]ryanodine binding activity of myometrial mem- 
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Fig. 2. Isolation and identification of a [3H]ryanodine binding protein 
from myometrial membrane fractions. (A) [3H]Ryanodine (i) and pro- 
tein (o) sedimentation profile of myometrial heavy SR membranes 
centrifuged through a 20~45% linear sucrose gradient. (B) [3H]Ry- 
anodine binding to myometrial membrane fractions using 12.5 nM 
[3H]ryanodine and varying protein concentration. The insert shows 
[3H]ryanodine binding to skeletal muscle SR membranes u ing 12.5 nM 
[3H]ryanodine. This clearly indicates the low levels of binding obtained 
with myometrial smooth muscle membranes. The data represent 
means + S.E.M. for four independent experiments each with duplicate 
samples. (C) Coomassie blue-stained SDS-polyacrylamide gradient (4- 
15%) gel of human myometrial membranes isolated on sucrose density 
gradient, gradient fractions 5 (A and B) and pooled ryanodine binding 
fractions 10-12 (C and D). The arrow demonstrates a polypeptide band 
found only in the ryanodine binding peak fractions with an estimated 
molecular mass of-  544 kDa. The molecular mass tandards shown are: 
carbonic anhydrase (29,000), egg albumin (45,000), bovine serum albu- 
min (66,000), phosphorylase b (97,400), fl-galactosidase (116,000) and 
myosin (205,000). 
branes was approximately 10% of the levels found with skeletal 
muscle membranes (Fig. 2B). For all experiments non-specific 
binding was taken as the binding measured in the presence of 
lmM unlabelled ryanodine in an identical sample and repre- 
sented 25% of total binding. Fig. 2C shows a 4-15% SDS 
polyacrylamide gradient gel of the sucrose gradient fractions 
where a band with an apparent molecular mass of ~544 kDa 
comigrated with the [3H]ryanodine binding peak. This band 
was absent in all other fractions examined. 
3.2. RT-PCR, cDNA cloning and cDNA sequencing of RyRI 
and RyR3 specific clones 
To determine the expression of the human RyR isoforms in 
myometrial tissue, RT-PCR was employed. The isolated total 
RNA and mRNA was used for an initial reverse transcription 
step to produce cDNA, followed by amplification of specific 
sequences by the PCR method. 
Using the published cDNA sequences for the human RyR1 
and RyR3 receptors, specific oligonucleotide probes were de- 
signed for amplification of each isoform. The human RyR2 
isoform sequence is not yet published and it was therefore not 
possible to design specific probes to investigate whether this 
isoform is also found in human myometrium. The specific PCR 
primers were designed to produce an 999 bp and 477 bp prod- 
uct, from the 3' region of RyR1 and RyR3 cDNA sequences, 
respectively (Fig. 3). Although the sequences are related, the 
oligonucleotide primers were taken from regions that showed 
the greatest sequence diversity in order to maximise selectivity. 
The specific PCR primers were designed to produce a PCR 
product hat encoded a section of the transmembrane spanning 
domains of each isoform. The purified RNA used for the initial 
reverse transcription reactions was treated with DNase to re- 
move any contaminating genomic DNA so that only cDNA 
produced by the reverse transcription could serve as template 
to produce the correct size of PCR products. 
cDNA sequence analysis of multiple independent isolates of 
the subcloned PCR products confirmed that each pair of prim- 
ers was specific for one of the two ryanodine mRNA species. 
Sequence analysis of the cDNAs revealed an open reading 
frame of 837 bp for RyR1 and 456 bp for RyR3 and their 
deduced amino acid sequences are indicated (Fig. 4A,B). Con- 
trols which lacked the reverse transcriptase enzyme gave no 
detectable PCR product, which confirmed that both RyRI and 
RyR3-specific PCR products were amplified from a cDNA 
template and not from genomic DNA. 
Restriction enzyme analysis of the human RyR3-specific 
PCR products indicated that the Hha! restriction endonuclease 
site predicted from the human RyR3 nucleotide sequence [21], 
was not present in any of the samples. The absence of the HhaI 
site was confirmed by direct sequence analysis howing that the 
published T position was a C [21]. This change in the base pair 
alters the codon such that the amino acid arginine at this posi- 
tion is replaced with cysteine. The substitution to cysteine at 
this position is in agreement with the RyR1 amino acid se- 
quence at position 4870 and the rabbit brain deduced amino 
acid sequence at position 4744 [28,20]. 837 bp of the RyRI 
RT-PCR products were sequenced following their cloning into 
M l3 and found to be identical to the published RyR1 sequence 
[28]. The RyR3-specific PCR primers amplified a 456 bp se- 
quence which was 94% homologous to the rabbit brain RyR 
cDNA sequence at position 14061-14516 [20]. Sequence analy- 
sis of the two myometrial-specific ryanodine receptor isoforms 
revealed 79% identity in nucleotide sequence between the trans- 
membrane spanning regions of these two isoforms. 
4. Discussion 
The present data describes the cloning and partial sequence 
analysis of cDNAs encoding two isoforms of the human ryan- 
odine receptor channel (RyRI and RyR3) in both pregnant and 
non-pregnant myometrial tissue and cultured myometrial 
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Fig. 3. RT-PCR of ryanodine receptors (RyR 1 and RyR3) in human myometrial smooth muscle. Polyacrylamide g l (6%) electrophoresis of RyR1 
and RyR3 RT-PCR products from human myometrial smooth muscle RNA. (A) The RyRl-specific oligonucleotides amplified a product of ~ 1 kb 
from cultured cells incubated with 1 ng/ml TGF-fl for 24 h (TGF), pregnant tissue (P) and non-pregnant tissue (NP). (B) The RyR3-specific 
oligonucleotides amplified a product of~500 bp from samples as indicated in A. Pregnant and non-pregnant RNA was treated with or without reverse 
transcriptase ( + RT) to show that the RT-PCR products were amplified from cDNA only. The nucleic acid marker lanes are indicated (M). 
smooth muscle cells. The work reported here also indicates that 
saponin-permeabilised myometrial smooth muscle cells are not 
activated by caffeine but exhibit ryanodine-sensitive Ca 2÷ re- 
lease when the intracellular stores are loaded with 45Ca2+. This 
ryanodine-sensitive Ca 2÷ release is augmented by the prior ap- 
plication of 10 mM caffeine to the permeabilised cell. This 
suggests that although caffeine does not release Ca > directly, 
it may modulate the activity of one or both isoforms in the 
presence of ryanodine by opening the CICR channel and allow- 
ing ryanodine to maintain them in an open state. This sensitisa- 
tion of the ryanodine-induced Ca 2÷ response by caffeine may 
indicate the contribution of the RyR1 isoform which may be 
less abundant than the RyR3 isoform. The demonstration f 
a membrane fraction from myometrial tissue that specifically 
bound [3H]ryanodine allowed the confirmation that aryan-  
odine-binding protein was indeed present in human myomet- 
rium. 
In this study RT-PCR has been used successfully to demon- 
strate the expression of two isoforms of the ryanodine receptor 
in pregnant and non-pregnant human myometrial smooth mus- 
cle tissue. The clone corresponding to the RyR1 isoform was 
837 bp in length and exhibits 100% identity to the reported 
human cDNA sequence [28], whereas the RyR3 specific clone 
was 456 bp in length and was identical to the reported human 
nucleotide sequence [21], except hat it contained a single base 
pair substitution. The C for T change in the RyR3 clones at 
position 172 may represent an allelic variation and not a PCR 
artefact, as this substitution was present in all clones prepared 
from four independent samples. This was also confirmed by the 
absence of any digested fragments obtained by the restriction 
~MSM RyRI  GATGACGTGAAGGGGCAGTGGGACCGACTGGTGCTCAACACGCCGTCTTTCCCTAGCAAC 6  HMSM RyRI  D D V K G Q W D R L V L N T P S F P S N 20 
HMSM RyR3 HMSM RyR3 
HMSM RyRI  TACTGGGACAAGTTTGTCAAGCGCAAGGTCCTC-GACAAACATGGGGACATCTACGGGCGG 120 HMSM RyR1 Y W D K F V K R K v L D K H G D I Y G R 40 
PdMSM RyR3 HMSM RyR3 
HMSM RyRI GAGCGGAT'~GCTGAGCTACTGGGCATGGACCTGGCCACACTAGAGATCACAGCCCACAAT 180 HMSM RyRI  E R I A E L L G M D L A T L E I T A H N 60 
HMSM RyR3 HMSM RyR3 
MMSM RyRI GAGCGCAAGCCCAACCCGCCGCCAGGGCTGCTGACC~CTCATGTCCATCGATGTCAAG 240 HMSM RyRI  E R K P N P P P G L L T W L M S I D V K 80 
HMSM RyR3 HMSM RyR3 
KMSM RyRI  TACCAGATC~AAGTTCGGGGTCATCTTCACAGACAACTCCTTCCTGTACCTGGGCTGG 300 HMSM RyRI  Y Q I W K F G V I F T D N S F L Y L G W i00 
HMSM RyR3 HMSM RyR3 
HMSM RyR1 TATATGGTGATGTCCCTC~ACACTACAACAACTTCTTCIq ' I~CTGCCCATCTCCTG 360 HMSM RyRI  Y M V M S L L G H Y N N F F F A A H L L 120 
~4SM RyR3 HMSM RyR3 
HMSM RyRI GACATCGCCATC-C~TCAAGACGCTGCGCACCATCC' /GTCCTC~TCACCCACAATGGG 420 HMSM RyRI  D I A M G V K T L R T I L S S V T H N G 140 
HMSM RyR3 GGCTTCAAGACACTGAGGACCATTCTGTCATCTGTAACTCACAATGGC 48 HMSM RyR3 G F K T L R T I L S S V T H N G 16 
HMSM RyRI  AAACAGCTGGTGATGACCGTGGGCCTTCTGGCGGTGGTCGTCTACC~TACACCGTGGTG 480 HMSM RyRI  K Q L V M T V G L L A V V V Y L Y T V V 160 
HMSM RyR3 AAACAGTTGGTTC~ACTGTCGGTCTCCTGGCCGTGGTGGTTTATCTCTATACTGTGGTG 108 HMSM RyR3 K Q L V L T V G L L A V V V Y L Y T V V 36 
HMSM RyRI  GCCTTCAACTTCTTCCGCAAGTTCTACAACAAGAGCGAGGATGAGGATGAACCTGACATG 540 ~MSM RyRI  A F N F F R K F Y N K S E D E D E P D M 180 
HMSM RyR3 GCTTTCAACTTC~FrCCGCAAGTTCTACAACAAAAGCGAAGACGATGACGAGCCCGATATG 168 HMSM RyR3 A F N F F R K F Y N K S E D D D E P D M 56 
KMSM RyRI AAGTGTGATGACATGATGACGTGTTACCTGTTTCACATGTACGTGGGTGTCCC~CTGGC 600 HMSM RyRI  K C D D M M T C Y L F H M Y V G V R A G 200 
HMSM RyR3 AAGTGCGACGACATGATGACGTGTFACCFFF ICCACATGTACGTGGGAGTGAGAGCAGGA 228 HMSM RyR3 K C D D M M T C Y L F H M Y V G V R A G 76 
HMSM RyRI GGAGGCA~FIVsGGGACGAGATCGAGGACCCCGCGGGTGACGAATACGAGCTCTACAGGGTG 660 HMSM RyRI  G G I G D E I E D P A G D E Y E L Y R V 220 
}~SM RyR3 GGTC-GCATTC-GTGATGA~TTGAAGACCCTGCTGGTGACCC~ATGAAATGTATCGCATT 288 HMSM RyR3 G G I G D E I E D P A G D P Y E M Y R I 96 
HMSM RyRI GTCTTCGACATCACC~CTTCTTC~CGTCATCGTCATCCTGTTGGCCATCATCCAGGGT 720 HMSM RyRI  V F D I T F F F F V I V I L L A I I Q G 240 
~qqSM RyR3 GTCT~ACATTACCiDL-F~CTTCTTCGTCATTGTCATCTTGCTGGCCATCATTCAAGGT 348 H/4SM RyR3 V F D I T F F F F V I V I L L A I I Q G 116 
HMSM RyR 1 C 'PGATCATCGACGCTTTTC-GTGAGCTCCGAGACCAACAAGAGCAAGTGAAGGAGGATATG 780 HMSM RyRI  L I I D A F G E L R D Q Q E Q v K E D M 260 
HMSM RyR3 CTTA~F~ATTGATGCTTTCGGAGAGCTAAGAGACCAGCAGGAACAAGTACGAGAAGATATG 408 h~SM RyR3 L I I D A F G E L R D Q Q Q R E  V E D M 136 
HMSM RyRI  GAGACC~AGTGCTTCATC~TGGAATCGGCAGTGACTACq~F~GATACGACACCGCAT S37 HMSM RyRI  E T K C F I C G I G S D Y F D T T P H 279 
HMSM RyR3 GAGACTAAATGTTTCATCTGTGGGATTGGCAATGACTACTTTGACACA 456 HMSM RyR3 E T K C F I C G I G N D Y F D T 152 
Fig. 4. cDNA sequence analysis of RyR 1 and RyR3-specific clones and deduced amino acid sequences from human myometrium. (A) Alignment 
of the nucleotide sequences of the human myometrial-specific RyR1 and RyR3 RT-PCR products. PCR products were cloned into M 13mp 18 and 
M 13mp 19 and sequenced asdescribed insectin 2. (B) Deduced amino acid sequences of the human myometrial RyR 1 and RyR3 RT-PCR products. 
The myometrial RyRI sequence is identical to residues 46914968 of the reported typel ryanodine receptor cDNA sequence (Zorzato et al., 1990). 
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endonuclease HhaI. This restriction site has been predicted 
from the published RyR3 nucleotide sequence [21]. Analysis of 
the deduced amino acid sequence reveals that this single base 
pair difference alters the amino acid sequence from arginine to 
~ysteine at this position and this site is identical to that found 
in the RyR1 isoform at residue 4870. We have been unable to 
detect he RyR2 isoform in myometrial smooth muscle as the 
human DNA sequence required to design specific primers for 
this isoform is at present unknown. The possible presence of 
this isoform in the myometrium remains to be determined be- 
fore an accurate stimation of the contribution of the various 
isoforms in Ca 2+ signalling can be established. 
[3H]Ryanodine binding assays using isolated heavy SR mem- 
branes from the myometrium confirmed the presence of a ryan- 
odine binding activity in this tissue. The amount of bound 
[3H]ryanodine was approximately 10% of that obtained with 
heavy SR membranes isolated from rabbit skeletal muscle, 
which contains a more extensive SR membrane system and so 
may reflect a difference in the contents of the receptor so lead- 
ing to higher levels of specific [3H]ryanodine binding. The com- 
paratively reduced levels of [3H]ryanodine binding protein iso- 
lated from the myometrium still enabled the estimation of its 
molecular mass by SDS gradient gel electrophoresis. Fractions 
isolated using sucrose density gradients were electrophoresed 
on a 4~15% gradient gel and a polypeptide of ~544 kDa was 
demonstrated in the fractions corresponding to the [3H]ryan- 
odine binding peak from the sedimentation profile, which was 
absent in all other fractions. The demonstration of the RyR 
using RT-PCR, while not allowing quantitative assessment of
the isoforms present, would appear to agree with the [3H]ryan- 
odine binding results. 
Recently there have been reports which demonstrate he co- 
existence of two isoforms of the ryanodine receptor in the same 
tissue type [12,36,12]. Previous studies carried out on bullfrog 
skeletal muscle identified two different isoforms (c~ and fl) of 
the ryanodine receptor in the same cell [37]. Further character- 
isation indicated that the primary structure of the c~ isoform 
was highly homologous (80%) to the RyR1 from rabbit skeletal 
muscle while the fl isoform is more than 85% identical to the 
RyR3 from rabbit brain. Takeshima nd co-workers have de- 
veloped a mouse model which contains a targeted mutation in 
the skeletal muscle ryanodine receptor gene [36]. The mutant 
muscle appears to lose its contractile response to electrical 
stimulation under physiological conditions but the Ca 2+ release 
response to caffeine is retained, which implies that another 
RyR other than the skeletal type contributes to Ca 2+ release in 
the mutant muscle. Ledbetter [12] selected primers to the 5' end 
of the RyRI, RyR2 and RyR3 cDNA sequences and amplified 
each of the isoforms by RT-PCR protocols to demonstrate he 
expression of two RyR isoforms in each type of porcine striated 
muscle and all RyR isoforms in a number of regions of the 
nervous ystem. In the uterus it is possible that at various tages 
of pregnancy different amounts of each isoform may be differ- 
entially expressed or regulated. If one isoform were to be more 
efficient in mobilising intracellular Ca 2÷, this manipulation of 
isoforms may alter the responsiveness and hence contractility 
of the intact issue. The balance between possible RyR isoforms 
and other intracellular Ca 2+ release receptors in myometrial 
smooth muscle, i.e. the InsP3 receptor, may play an important 
role in maintaining the uterus in a quiescent state during preg- 
nancy until early labour when the levels of important regulatory 
proteins are increased, e.g. gap junctions, ion channels, prosta- 
glandin and oxytocin receptors. 
This work may be the first indication of dual expression of 
ryanodine receptor isoforms in human smooth muscle tissue 
but the possibility cannot be excluded that the samples and 
cultures of human myometrium contain at least two different 
cell types each expressing a single isoform of the ryanodine 
receptor/channel complex. However, morphological analysis 
and antibody staining for ~-actin indicate that the cultures are 
exclusively smooth muscle and not a mixed cell population. 
The work presented here has demonstrated for the first time 
evidence for the co-expression fat least wo RyR isoforms and 
the presence of a ryanodine-binding protein from human 
myometrial smooth muscle. The current methods do not allow 
any quantitative assessment of the amount of mRNA tran- 
scripts present or in what proportions these different isoforms 
may occur. Until this is known, the detailed physiological sig- 
nificance for the expression of two isoforms in the same cell 
remains obscure. 
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